CN114728952A - 一种鲁拉西酮盐酸盐的制备方法 - Google Patents
一种鲁拉西酮盐酸盐的制备方法 Download PDFInfo
- Publication number
- CN114728952A CN114728952A CN202080081396.0A CN202080081396A CN114728952A CN 114728952 A CN114728952 A CN 114728952A CN 202080081396 A CN202080081396 A CN 202080081396A CN 114728952 A CN114728952 A CN 114728952A
- Authority
- CN
- China
- Prior art keywords
- lurasidone
- hydrochloric acid
- acid solution
- hydrochloride
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002863 lurasidone hydrochloride Drugs 0.000 title claims abstract description 30
- NEKCRUIRPWNMLK-SCIYSFAVSA-N lurasidone hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 NEKCRUIRPWNMLK-SCIYSFAVSA-N 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 61
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims abstract description 30
- 229960001432 lurasidone Drugs 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 20
- 239000003513 alkali Substances 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 18
- 239000012046 mixed solvent Substances 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 58
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 17
- 238000001816 cooling Methods 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000012458 free base Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940035437 1,3-propanediol Drugs 0.000 claims description 2
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 2
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 claims description 2
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 2
- 229940093476 ethylene glycol Drugs 0.000 claims description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 1
- 239000013557 residual solvent Substances 0.000 abstract description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000010992 reflux Methods 0.000 description 33
- 238000003756 stirring Methods 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 16
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 12
- 239000012065 filter cake Substances 0.000 description 11
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 2
- 229940127236 atypical antipsychotics Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- -1 1,2 benzisothiazol-3-yl Chemical group 0.000 description 1
- GFHNMKBZLROYLH-UHFFFAOYSA-N 4-methylisoindole-1,3-dione hydrochloride Chemical compound Cl.CC1=C2C(C(=O)NC2=O)=CC=C1 GFHNMKBZLROYLH-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- AKPUJVVHYUHGKY-UHFFFAOYSA-N hydron;propan-2-ol;chloride Chemical compound Cl.CC(C)O AKPUJVVHYUHGKY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940036674 latuda Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本发明提供了一种盐酸鲁拉西酮的制备方法,包括在醇类溶剂和卤代烷类溶剂的混合溶剂中,鲁拉西酮游离碱与盐酸反应得到盐酸鲁拉西酮。本发明提供的方法,收率高,成本低,安全性高,残留溶剂低,非常适合工业化生产。
Description
PCT国内申请,说明书已公开。
Claims (10)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911346683.5A CN113024535B (zh) | 2019-12-24 | 2019-12-24 | 一种鲁拉西酮盐酸盐的制备方法 |
CN2019113466835 | 2019-12-24 | ||
PCT/CN2020/134285 WO2021129364A1 (zh) | 2019-12-24 | 2020-12-07 | 一种鲁拉西酮盐酸盐的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114728952A true CN114728952A (zh) | 2022-07-08 |
CN114728952B CN114728952B (zh) | 2024-08-20 |
Family
ID=76451609
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911346683.5A Active CN113024535B (zh) | 2019-12-24 | 2019-12-24 | 一种鲁拉西酮盐酸盐的制备方法 |
CN202080081396.0A Active CN114728952B (zh) | 2019-12-24 | 2020-12-07 | 一种鲁拉西酮盐酸盐的制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911346683.5A Active CN113024535B (zh) | 2019-12-24 | 2019-12-24 | 一种鲁拉西酮盐酸盐的制备方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230037151A1 (zh) |
CN (2) | CN113024535B (zh) |
WO (1) | WO2021129364A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115043830A (zh) * | 2022-07-01 | 2022-09-13 | 浙江美诺华药物化学有限公司 | 一种鲁拉西酮二盐酸盐晶型的制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123858A1 (en) * | 2011-03-14 | 2012-09-20 | Ranbaxy Laboratories Limited | Amorphous lurasidone hydrochloride |
WO2013132511A1 (en) * | 2012-03-09 | 2013-09-12 | Hetero Research Foundation | Novel polymorph of lurasidone hydrochloride |
CN104031041A (zh) * | 2013-03-06 | 2014-09-10 | 江苏恩华药业股份有限公司 | 盐酸鲁拉西酮的新晶型及其制备方法 |
CN106397424A (zh) * | 2016-03-30 | 2017-02-15 | 北京万全德众医药生物技术有限公司 | 盐酸鲁拉西酮氧化杂质的一种制备方法 |
CN106518729A (zh) * | 2016-09-21 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 盐酸鲁拉西酮中间体的制备方法 |
CN106916151A (zh) * | 2015-12-28 | 2017-07-04 | 苏州二叶制药有限公司 | 一种盐酸鲁拉西酮的制备方法 |
WO2017154021A1 (en) * | 2016-03-09 | 2017-09-14 | Zcl Chemicals Ltd. | An improved process for the preparation of lurasidone base and its salt |
CN110114063A (zh) * | 2017-01-06 | 2019-08-09 | 广东东阳光药业有限公司 | 鲁拉西酮固体分散体及其制备方法 |
-
2019
- 2019-12-24 CN CN201911346683.5A patent/CN113024535B/zh active Active
-
2020
- 2020-12-07 CN CN202080081396.0A patent/CN114728952B/zh active Active
- 2020-12-07 US US17/787,369 patent/US20230037151A1/en active Pending
- 2020-12-07 WO PCT/CN2020/134285 patent/WO2021129364A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012123858A1 (en) * | 2011-03-14 | 2012-09-20 | Ranbaxy Laboratories Limited | Amorphous lurasidone hydrochloride |
WO2013132511A1 (en) * | 2012-03-09 | 2013-09-12 | Hetero Research Foundation | Novel polymorph of lurasidone hydrochloride |
CN104031041A (zh) * | 2013-03-06 | 2014-09-10 | 江苏恩华药业股份有限公司 | 盐酸鲁拉西酮的新晶型及其制备方法 |
CN109705112A (zh) * | 2013-03-06 | 2019-05-03 | 江苏恩华药业股份有限公司 | 盐酸鲁拉西酮的新晶型的制备方法 |
CN106916151A (zh) * | 2015-12-28 | 2017-07-04 | 苏州二叶制药有限公司 | 一种盐酸鲁拉西酮的制备方法 |
WO2017154021A1 (en) * | 2016-03-09 | 2017-09-14 | Zcl Chemicals Ltd. | An improved process for the preparation of lurasidone base and its salt |
CN106397424A (zh) * | 2016-03-30 | 2017-02-15 | 北京万全德众医药生物技术有限公司 | 盐酸鲁拉西酮氧化杂质的一种制备方法 |
CN106518729A (zh) * | 2016-09-21 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 盐酸鲁拉西酮中间体的制备方法 |
CN110114063A (zh) * | 2017-01-06 | 2019-08-09 | 广东东阳光药业有限公司 | 鲁拉西酮固体分散体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114728952B (zh) | 2024-08-20 |
US20230037151A1 (en) | 2023-02-02 |
WO2021129364A1 (zh) | 2021-07-01 |
CN113024535B (zh) | 2024-08-02 |
CN113024535A (zh) | 2021-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106810426B (zh) | 一种大麻二酚的合成方法 | |
CN107445909B (zh) | 一种丙硫菌唑中间体的制备方法 | |
CN114728952A (zh) | 一种鲁拉西酮盐酸盐的制备方法 | |
CN112079848A (zh) | 巴洛沙韦关键中间体的合成方法 | |
CN111548310B (zh) | 一种左西孟旦钠晶型及其制备方法 | |
US20210155651A1 (en) | Process for the preparation of iron (iii) carboxymaltose | |
CN115073444A (zh) | 一种盐酸鲁拉西酮环氧杂质的精制去除方法 | |
CN112266390B (zh) | 一种巴洛沙韦中间体的制备方法 | |
CN112521421A (zh) | 一种药物化合物的制备方法 | |
CN112480172A (zh) | 硼烷-吡啶络合物在制备药物化合物中的用途 | |
CN107118169B (zh) | 4-氨基-6-特丁基-3-甲硫基-1,2,4-三嗪-5(4h)-酮的合成方法 | |
CN111004255A (zh) | 一种头孢卡品内酯化合物或其盐酸盐的制备方法 | |
JP4810136B2 (ja) | ジヒドロベンゾピラン化合物の製造方法 | |
KR101004187B1 (ko) | 1,2-디클로로에탄 프리 조니사미드 결정 및 고순도조니사미드 결정의 제조방법 | |
CN111196807A (zh) | 一种阿维巴坦钠的回收制备方法 | |
CN112375060B (zh) | 一种盐酸奥洛他定的后处理纯化方法 | |
CN108610341B (zh) | 一种米氮平合成及后处理方法 | |
JP6275596B2 (ja) | テルミサルタンのアンモニウム塩の製造方法 | |
JP4749759B2 (ja) | ジヒドロベンゾピラン化合物の製造方法 | |
CN108752290B (zh) | 一种绿色合成磷酸苯丙哌林中间体的方法 | |
CN107674067B (zh) | 一种伊匹哌唑的纯化方法 | |
CN105330615B (zh) | 一种沃替西汀的制备方法 | |
CN106883223B (zh) | 一种Brexpiprazole盐酸盐的纯化方法 | |
CN114195783A (zh) | 一种左旋吡喹酮的制备方法 | |
CN118307537A (zh) | 一种吡喹酮杂质rrt0.76的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |